Literature DB >> 3230164

Distribution of muscarinic receptor subtypes within architectonic subregions of the primate cerebral cortex.

D C Mash1, W F White, M M Mesulam.   

Abstract

The regional distributions of muscarinic receptor subtypes (M1 and M2) in the macaque brain were investigated by in vitro receptor autoradiography. Putative muscarinic receptor subtypes were distinguished by their differential affinities for pirenzepine and carbachol in competition with [3H]-quinuclidinyl benzilate. Autoradiographic visualization of muscarinic receptor subtypes demonstrated marked regional and laminar variations that respected architectonic boundaries. The M1 receptor subtype was widely distributed throughout most cortical areas and was most intense over the superficial layers. Almost all limbic and paralimbic regions including the amygdala, hippocampus, orbitofrontal, temporopolar, parahippocampal, cingulate, and parolfactory areas displayed peak densities of the M1 receptor subtype. The M2 receptor subtype was selectively elevated in the primary sensory areas of all five sensory modalities, including the visual (area 17, V1), auditory (A1), and somatosensory (3b, S1) koniocortices, the anterior olfactory nucleus, and the gustatory area. The primary motor area also displayed a relative peak of M2 receptor subtype labeling. In the hippocampal formation, M1, M2, and nicotine receptors were distributed differentially, with each subdivision having a specific complement of cholinergic receptor subtype. The M1 receptor subtype was prevalent in the dentate gyrus, the CA4-CA3 region, and the CA1 ammonic sector. The M2 receptor subtype was concentrated in the CA2 sector, the subiculum, the rhinal cortices, and the parasubiculum. Putative neural nicotinic receptors, tagged with L-[3H]-nicotine, were most concentrated within the presubiculum.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3230164     DOI: 10.1002/cne.902780209

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  20 in total

1.  Neuronal localization of m1 muscarinic receptor immunoreactivity in the rat basolateral amygdala.

Authors:  Alexander Joseph McDonald; Franco Mascagni
Journal:  Brain Struct Funct       Date:  2010-05-26       Impact factor: 3.270

Review 2.  Transmitter receptors and functional anatomy of the cerebral cortex.

Authors:  Karl Zilles; Nicola Palomero-Gallagher; Axel Schleicher
Journal:  J Anat       Date:  2004-12       Impact factor: 2.610

3.  The M1 Muscarinic Receptor Antagonist VU0255035 Delays the Development of Status Epilepticus after Organophosphate Exposure and Prevents Hyperexcitability in the Basolateral Amygdala.

Authors:  Steven L Miller; Vassiliki Aroniadou-Anderjaska; Volodymyr I Pidoplichko; Taiza H Figueiredo; James P Apland; Jishnu K S Krishnan; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2016-10-31       Impact factor: 4.030

4.  Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission.

Authors:  L Mrzljak; A I Levey; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

5.  Bacterial artificial chromosome transgenic analysis of dynamic expression patterns of regulator of G-protein signaling 4 during development. I. Cerebral cortex.

Authors:  P J Ebert; D B Campbell; P Levitt
Journal:  Neuroscience       Date:  2006-09-25       Impact factor: 3.590

6.  Neuronal localization of M2 muscarinic receptor immunoreactivity in the rat amygdala.

Authors:  A J McDonald; F Mascagni
Journal:  Neuroscience       Date:  2011-08-19       Impact factor: 3.590

7.  Age-dependent decrease in the affinity of muscarinic M1 receptors in neocortex of rhesus monkeys.

Authors:  M G Vannucchi; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

8.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 9.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

10.  Paraneoplastic antigen-like 5 gene (PNMA5) is preferentially expressed in the association areas in a primate specific manner.

Authors:  Masafumi Takaji; Yusuke Komatsu; Akiya Watakabe; Tsutomu Hashikawa; Tetsuo Yamamori
Journal:  Cereb Cortex       Date:  2009-04-14       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.